公开(公告)号：EP2471938A2

公开(公告)日：2012-07-04

申请号：EP12161534.8

申请日：2005-11-24

Applicant: The Research Foundation for Microbial Diseases of Osaka University ,  National Institute of Biomedical Innovation

Inventor： Mori, Yasuko ,  Somboonthum, Pranee ,  Yoshii, Hironori ,  Gomi, Yasuyuki ,  Takahashi, Michiaki ,  Yamanishi, Koichi

IPC: C12N15/869 ,  A61K39/165 ,  A61K39/25 ,  A61K39/295 ,  A61P31/22 ,  A61P37/04 ,  C12N5/00 ,  C12N7/00

CPC classification number: A61K39/25 ,  A61K39/12 ,  A61K39/165 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/70 ,  C12N15/86 ,  C12N2710/16734 ,  C12N2710/16743 ,  C12N2710/16762 ,  C12N2760/18734 ,  C12N2800/204 ,  C12N2800/50 ,  C12N2820/55 ,  Y02A50/39 ,  Y02A50/394

Abstract: The problems to be solved by the present invention are to provide: a recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing a recombinant varicella-zoster virus; a vector containing a BAC vector sequence in the specific gene of a genomic gene of varicella-zoster virus; cells containing such a vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; a nucleic acid cassette containing the BAC vector sequence; and a multivalent vaccine. The above problems were solved by developing a process for producing a recombinant varicella-zoster virus, wherein the BAC vector sequence is inserted into a specific virus gene.

公开(公告)号：EP2458003A1

公开(公告)日：2012-05-30

申请号：EP11004408.8

申请日：2005-12-22

Applicant: The Research Foundation for Microbial Diseases of Osaka University

Inventor： Morita, Kouichi ,  Nabeshima, Takeshi ,  Miyake, Shinichi ,  Onishi, Toshiyuki ,  Fuke, Isao ,  Ishikawa, Toyokazu ,  Goda, Hideo ,  Ishibashi, Masahide ,  Takahashi, Michiaki

IPC: C12N15/09 ,  A61K39/12 ,  A61K39/295 ,  A61P31/12 ,  C12N7/00 ,  C12N7/04

CPC classification number: A61K39/12 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2770/24134 ,  C12N2770/24161 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/396

Abstract: A nucleic acid molecule containing nucleotide sequences that encode the capsid protein, pre-membrane protein and non-structural protein of Japanese encephalitis virus, and a nucleotide sequence that encodes the envelop protein of a second flavivirus, wherein the nucleotide sequence(s) that encode(s) the pre-membrane protein and/or non-structural protein of Japanese encephalitis virus contain(s) nucleotide mutations that produce one or more amino acid mutations that attenuate the virus.

Abstract translation: 含有编码日本脑炎病毒的衣壳蛋白，膜前蛋白质和非结构蛋白质的核苷酸序列的核酸分子和编码第二黄病毒的包膜蛋白的核苷酸序列，其中编码的核苷酸序列 日本脑炎病毒的膜前蛋白和/或非结构蛋白含有产生一种或多种减毒病毒的氨基酸突变的核苷酸突变。

公开(公告)号：EP2413961A1

公开(公告)日：2012-02-08

申请号：EP10714104.6

申请日：2010-03-31

Applicant: Japan As Represented By Director-General Of National Institute Of Infectious Diseases ,  THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  Toko Yakuhin Kogyo Kabushiki Kaisha

Inventor： HASEGAWA, Hideki ,  MANABE, Sadao ,  TANIMOTO, Takeshi ,  MIYAZAKI, Takashi ,  KAMISHITA, Taizou

IPC: A61K39/145 ,  A61K39/39 ,  C07K14/11

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/543 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/58 ,  A61K2039/6093 ,  C12N2760/16134

Abstract: The present invention provides a vaccine composition for transnasal mucous membrane administration, which contains an influenza virus antigen, polyriboinosinic polyribocytidylic acid (poly (I:C)) or a derivative thereof and a carboxyvinyl polymer. The present invention also provides a prophylactic method of influenza, including a step of administering the vaccine composition at least once to the nasal mucosa of a subject in need thereof.

公开(公告)号：EP2127671A1

公开(公告)日：2009-12-02

申请号：EP08710949.2

申请日：2008-02-07

Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  National University Corporation Kochi University

Inventor： UDAKA, Keiko ,  ISHIBASHI, Masahide

IPC: A61K39/39 ,  A61K39/00 ,  A61K39/102 ,  A61K39/12 ,  A61K39/29 ,  A61P31/12 ,  A61P35/00 ,  C07K14/235 ,  C07K14/82

CPC classification number: A61K39/099 ,  A61K39/0011 ,  A61K2039/521 ,  A61K2039/55505 ,  A61K2039/55594 ,  C07K14/4747 ,  C07K14/4748 ,  Y02A50/386

Abstract: The present invention provides an adjuvant for cancer antigen peptide vaccines and virus antigen peptides, containing a pertussis vaccine as a primary ingredient. The present invention also provides a therapeutic agent for a cancer or viral infectious disease, and a prophylactic agent for metastasis or recurrence of cancer or onset of virus-induced tumor, containing a cancer antigen peptide or virus antigen peptide and a pertussis vaccine. A pertussis vaccine that can be suitably used is a whole cell body pertussis vaccine. The agents of the present invention can be safely administered in a plurality of doses.

Abstract translation: 本发明提供了含有百日咳疫苗作为主要成分的癌抗原肽疫苗和病毒抗原肽的佐剂。 本发明还提供了癌症或病毒感染性疾病的治疗剂，以及含有癌抗原肽或病毒抗原肽和百日咳疫苗的癌症转移或复发或病毒诱导肿瘤发作的预防剂。 可以适当使用的百日咳疫苗是全细胞体百日咳疫苗。 可以以多个剂量安全地施用本发明的药剂。

公开(公告)号：EP0572737B1

公开(公告)日：2001-02-28

申请号：EP92311006.8

申请日：1992-12-02

Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

Inventor： Saito, Atsushi ,  Sinagawa, Hideo ,  Nakata, Atsuo

IPC: C12N15/49 ,  C12N15/62 ,  A61K39/21 ,  C07K14/00 ,  G01N33/53

CPC classification number: C07K14/005 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2740/16322 ,  Y10S435/974

公开(公告)号：EP0949333A1

公开(公告)日：1999-10-13

申请号：EP98923127.9

申请日：1998-06-04

Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

Inventor： UEDA, Shigeharu ,  WATANABE, Michiko ,  KAWANISHI, Hitomi

IPC: C12N15/45 ,  C07K14/115 ,  C07K7/06 ,  A61K39/165 ,  A61K48/00

CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K2039/51 ,  A61K2039/525 ,  A61K2039/53 ,  C12N2760/18422

Abstract: Mutant measles virus antigens containing at least one protein antigen selected from the group consisting of (I) mutant measles virus H protein antigens and (II) mutant measles virus F protein antigens as specified below: (I) at least one measles virus H protein selected from the group consisting of a full-length protein of an amino acid sequence consisting of 617 amino acids in total described in SEQ ID NO.2 or 10 and specified peptide fragments thereof, and (II) at least one measles virus F protein antigen selected from the group consisting of a full-length protein of an amino acid sequence consisting of 550 amino acids in total described in SEQ ID NO:18 or 20 specified peptide fragment thereof; and mutant measles virus genes containing genes encoding the above measles virus antigens. The use of these antigens or genes encoding the same makes it possible to efficiently and economically provide attenuated live measles vaccines or gene vaccines suitable for epidemic measles virus stains and diagnostics for appropriately detecting the infection with epidemic measles virus stains.

Abstract translation: 含有选自（I）突变型麻疹病毒H蛋白抗原和（II）突变型麻疹病毒F蛋白抗原中的至少一种蛋白质抗原的突变型麻疹病毒抗原，如下所述：（I）至少一种选择的麻疹病毒H蛋白 来自由SEQ ID NO.2或10中总共617个氨基酸组成的氨基酸序列的全长蛋白质及其特定的肽片段组成的组，和（II）至少一种选择的麻疹病毒F蛋白抗原 由全部由SEQ ID NO：18所示的550个氨基酸组成的氨基酸序列的全长蛋白质或其特定的肽片段组成的组; 和含有编码上述麻疹病毒抗原的基因的突变麻疹病毒基因。 使用这些抗原或编码这些抗原的基因使得可以有效地和经济地提供适合于流行性麻疹病毒染色体的减毒活疫苗或基因疫苗，以及用于适当检测流行性麻疹病毒染色体的感染的诊断。

公开(公告)号：EP0933426A1

公开(公告)日：1999-08-04

申请号：EP99106005.4

申请日：1990-12-28

Applicant: The Research Foundation for Microbial Diseases of Osaka University

Inventor： Okayama, Hiroto ,  Fuke, Isao ,  Mori, Chisato ,  Takamizawa, Akihisa ,  Yoshida, Iwao

IPC: C12N15/40 ,  C07K14/18 ,  A61K39/29 ,  C12Q1/70 ,  G01N33/569

CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N2770/24222

Abstract: Disclosed are isolated non-A, non-B hepatitis virus genomic cDNA fragments of the entire region of the virus gene nucleotide sequence from the 1st to 9416th nucleotides shown in Fig. 2(1) through Fig. 2(16) hereof. The fragments are in particular a cDNA covering the sequence from the 333rd to the 422nd nucleotide, the coding region from the 333rd to 9362nd nucleotides. The cDNA fragments and antigen polypeptide expression products thereof are useful as a diagnostic reagent for non-A, non-B hepatitis. The antigen polypeptide is also useful as an active ingredient for a non-A, non-B hepatitis virus vaccine.

Abstract translation: 公开了图1所示的第1至第9416位核苷酸的病毒基因核苷酸序列的整个区域的分离的非A非乙型肝炎病毒基因组cDNA片段。 2（1）至图 2（16） 该片段特别是涵盖从第333到第422个核苷酸的序列的cDNA，编码区是从333到9362个核苷酸。 其cDNA片段及其抗原多肽表达产物可用作非A非乙型肝炎的诊断试剂。 抗原多肽也可用作非A非乙型肝炎病毒疫苗的活性成分。

公开(公告)号：EP0485611B1

公开(公告)日：1999-03-17

申请号：EP90917690.1

申请日：1990-11-30

Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

Inventor： SAITO, Atsushi, Kanonji Inst. Research Foundation ,  TANAKA, Naoto, Kanonji Inst. Research Foundation ,  SHINAGAWA, Hideo, D-17-204, 1-24, Satakedai ,  NAKATA, Atsuo, 1-201, 6-24, Higashitoyonaka-cho

IPC: C12N15/48 ,  C12N15/49 ,  C12N1/21 ,  C12R1/19

CPC classification number: C07K14/005 ,  A61K38/00 ,  C12N9/1276 ,  C12N9/506 ,  C12N15/00 ,  C12N15/70 ,  C12N2740/16022 ,  C12N2740/16222 ,  C12N2740/16322

Abstract: Three kinds of core protein coded for with a gag gene and three kinds of enzyme coded for with a pol gene are each separately mass-produced as a mature or active protein by inserting cDNA fragments containing at least protease genes among retrovirus genes into mass-expressed genes and directly gene expressing vectors to prepare a plasmid, expressing retrovirus genes therewith, and processing the product of expression per se with a protease present in said product. Alternatively, cDNA fragments containing a nef gene domain of HIV is inserted into mass-expressed genes and directely gene expressing vectors to prepare a plasmid, with which a Nef protein is mass-produced as the product of expression of a nef gene.

公开(公告)号：EP0867510A1

公开(公告)日：1998-09-30

申请号：EP98201297.3

申请日：1990-11-30

Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

Inventor： Saito, Atsushi, Kanonji Inst., The Res. Found. for ,  Tanaka, Natao, Kanonji inst., the res. found. for ,  Shingawa, Hideo ,  Nakata, Atsuo

IPC: C12N15/55 ,  C12N15/48 ,  C12N9/50 ,  C07K14/16

CPC classification number: C07K14/005 ,  A61K38/00 ,  C12N9/1276 ,  C12N9/506 ,  C12N15/00 ,  C12N15/70 ,  C12N2740/16022 ,  C12N2740/16222 ,  C12N2740/16322

Abstract: The present invention provides a method of preparing a plasmid having both expressing ability of retroviral genes and after-translational processing, and the resultant plasmid and the expression products thereof.
The method of the present invention is to prepare a plasmid by insertion-linking a cDNA fragment containing at least protease gene from among retroviral genes with a highly expressing gene or a gene direct expressing vector, thereby causing expression of the retroviral genes, and at the same time, to process said expression product itself with protease in that expression product, thereby mass-producing three kinds of core protein encoded by gag gene, and three kinds of enzyme encoded by pol gene, in the form of individual single mature or active protein.

Abstract translation: 本发明提供了制备具有逆转录病毒的基因的表达都能力和后翻译加工，将得到的质粒和其表达产物的质粒的方法。 本发明的方法是通过制备质粒插入联的cDNA片段含有来自反转录病毒的基因具有高度表达的基因或基因直接表达载体，从而使逆转录病毒基因的表达中的至少蛋白酶基因，并且在 的Sametime，以处理所述表达产物本身与该表达产物的蛋白酶，从而批量生产3种核心蛋白由gag基因编码的，和3种由pol基因编码的酶的，在个别单成熟或活性蛋白的形式 ，

公开(公告)号：EP0510996B1

公开(公告)日：1998-09-16

申请号：EP92303705.5

申请日：1992-04-24

Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

Inventor： Shiraki, Kimiyasu ,  Takahashi, Michiaki

IPC: C12N15/86 ,  C07K14/00 ,  C12N7/01 ,  A61K39/29 ,  A61K39/25 ,  A61K39/295 ,  C12N15/51 ,  G01N33/53

CPC classification number: G01N33/56983 ,  A61K39/00 ,  A61K39/12 ,  A61K39/25 ,  A61K2039/5254 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/16722 ,  C12N2710/16734 ,  C12N2710/16743 ,  C12N2730/10122 ,  C12N2730/10134 ,  G01N33/56994